Abstract: A magnetic resonance scanner has a base, a C-arm mounted on said base, the C-arm having an inner surface curved in a C-shape, the C-shape defining a plane, a magnet mounted on said inner curved surface of said C-arm, the magnet generating a basic magnetic field for magnetic resonance imaging, and a drive mechanism mechanically connected to the magnet. The drive mechanism rotates the magnet around an axis that is orthogonal to said plane so as to selectively position said magnet in at least two magnet positions that are respectively above and beneath a patient, who is situated in the C-arm along or parallel to the axis.

Abstract: The present invention includes a low dose and sustained release formulation of 2,4-dinitrophenol (DNP). The compositions of the invention are useful for preventing or treating a disease or disorder, such as non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, insulin resistance and/or diabetes, in a subject in need thereof.

Abstract: Genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein are provided. Also provided are genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein that have been engrafted with human cells such as human hematopoietic cells, and methods for making such engrafted mice. These mice find use in a number of applications, such as in modeling human immune disease and pathogen infection; in in vivo screens for agents that modulate hematopoietic cell development and/or activity, e.g. in a healthy or a diseased state; in in vivo screens for agents that are toxic to hematopoietic cells; in in vivo screens for agents that prevent against, mitigate, or reverse the toxic effects of toxic agents on hematopoietic cells; in in vivo screens of human hematopoietic cells from an individual to predict the responsiveness of an individual to a disease therapy, etc.

Abstract: Genetically modified non-human animals are provided that may be used to model human hematopoietic cell development, function, or disease. The genetically modified non-human animals comprise a nucleic acid encoding human IL-6 operably linked to an IL-6 promoter. In some instances, the genetically modified non-human animal expressing human IL-6 also expresses at least one of human M-CSF, human IL-3, human GM-CSF, human SIRPa or human TPO. In some instances, the genetically modified non-human animal is immunodeficient. In some such instances, the genetically modified non-human animal is engrafted with healthy or diseased human hematopoietic cells. Also provided are methods for using the subject genetically modified non-human animals in modeling human hematopoietic cell development, function, and/or disease, as well as reagents and kits thereof that find use in making the subject genetically modified non-human animals and/or practicing the subject methods.

Abstract: The present invention includes DNP derivatives that are useful for preventing or treating a metabolic disease or disorder in a subject in need thereof. In certain embodiments, the subject is further administered at least one additional therapeutic agent.

Abstract: One aspect of the invention provides a method for drift correction to correct a 3D point collection dataset to compensate for drift over time. The method includes: (a) separating the 3D dataset into n segments, wherein n>1; (b) for each of the n segments, reconstructing a volume image as a 3D histogram in which a count for each voxel in the histogram equals a number of localization estimates falling within the voxel; (c) performing 3D cross-correlation between pairs of the n segments; (d) identifying a correlation peak in a result of the 3D cross-correlation to determine a shift distance between pairs of the n segments; (e) solving an overdetermined system of shift distances to determine independent shifts; and (f) offsetting positions from a plurality of segments in the 3D point collection dataset with the independent shifts calculated in step (e) to correct for drift.

Abstract: The present invention includes methods and compositions for increasing longevity of a cell and increasing cellular resistance to stress. In certain embodiments, the invention includes a method to induce gene expression of a homolog of Pachytene Checkpoint 2 (pch-2) or bmk-1 gene. The present invention also includes methods to treat oxidative stress or induce cellular death or apoptosis by administering a composition comprising a modulator of pch-2 or bmk-1 homolog gene expression.

Abstract: The invention relates to the identification of secretory antibody-bound bacteria in the microbiota in a subject that influence the development and progression of inflammatory diseases and disorders. Thus, the invention relates to compositions and methods for detecting and identifying the constituents of a subject's microbiota, methods of modifying the constituents of the microbiota, and methods for treating inflammatory diseases and disorders in a subject in need thereof.

Abstract: According to some aspects, a quantum information system is provided that includes an ancilla qubit; a qudit coupled to the ancilla qubit, a detector configured to generate a detection result based on a quantum state of the ancilla qubit, and a driving source coupled to the qudit and the ancilla qubit and configured to apply at least one qudit driving signal to the qudit based on the detection result and at least one qubit driving signal to the qudit based on the detection result.

Abstract: Techniques for modifying the Josephson potential of a transmon qubit by shunting the transmon with an inductance are described. The inclusion of this inductance may increase the confined potential of the qubit system compared with the conventional transmon, which may lead to a transmon qubit that is stable at much higher drive energies. The inductive shunt may serve the purpose of blocking some or all phase-slips between the electrodes of the qubit. As a result, the inductively shunted transmon may offer an advantage over conventional devices when used for applications involving high energy drives, whilst offering few to no drawbacks in comparison to conventional devices when used at lower drive energies.

Abstract: According to some aspects, a spectrometer is provided, the spectrometer configured to receive molecules of a plurality of metabolites including one or more molecules of a first metabolite, filter the received molecules to retain molecules of the first metabolite including a plurality of different mass isotopomers of the first metabolite, fragment molecules of a first mass isotopmer of the retained molecules to produce a first plurality of daughter ions, measure abundances of the first plurality of daughter ions as a function of daughter ion mass, fragment molecules of a second istopomer, different from the first mass isotopmer, of the retained molecules to produce a second plurality of daughter ions, and measure abundances of the second plurality of daughter ions as a function of the daughter ion mass.

Abstract: The present invention relates to novel methods and compositions for increasing AMPK activity and glucose uptake comprising administering a macrophage migration inhibitory factor (MIF) pathway agonist in a subject in need thereof. The invention also relates to methods for selecting a subject for treatment with an agonist of MIF, identifying a subject at risk for developing a condition in which increased AMPK activity is desirable, and for predicting whether a subject is susceptible to a condition in which increased AMPK activity is desirable.

Abstract: Nanoparticulate compositions are disclosed. The nanoparticulate compositions typically include at least one, preferably two or more, active agent(s), one of which is an immunomodulatory compound, loaded into, attached to the surface of and/or enclosed within a delivery vehicle. The delivery vehicles can be nanolipogels including a polymeric core and a lipid shell or a biodegradable polymeric nanoparticle such as a PLGA nanoparticle. Typically, at least one of the active agents is an immunomodulator that increases an immune stimulatory response or decreases an immune suppressive response. In some embodiments, the particle includes both an immunomodulator that increases an immune stimulatory response and an immunomodulator that decreases an immune suppressive response. The particles can be decorated with a targeting moiety that improves delivery to a target cell. Methods of using the compositions to enhance an immune response and treat diseases such as cancer are also disclosed.

Abstract: Provided herein are compositions, methods and uses involving antibodies that bind to ErbB, a receptor tyrosine kinase, and modulate the activity of ErbB. Also provided are uses and methods for treating disorders, such as cancer, by administering to subject an antibody that binds to ErbB.

Abstract: The invention features methods and compositions for eliciting an anti-tumor response in a subject comprising administering to the subject a pHLIP® construct comprising an antibody recruiting molecule linked to one or more pHLIP® peptides by a non-cleavable linker compound. The construct increases the amount of the antibody recruiting molecule on the surface of a diseased cell.

Abstract: A heart failure recovery device includes a fluid pump having an inlet and an outlet in fluid communication with a pump reservoir, and a pumping element disposed within the pump reservoir, the pumping element including a protrusion that in an active state is configured to rotate and move fluid away from the inlet and towards the outlet. A receiver coil can be electrically coupled to the fluid pump and is configured to subcutaneously absorb electromagnetic energy for powering the fluid pump. In certain embodiments, an implantable port provides fluid access to the pump reservoir for cleaning and maintaining the fluid pump. In other embodiments, a valve closes fluid access to at least one of the inlet and the outlet during periods when the device is not being used for treatment.

Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins that are degraded and/or otherwise inhibited by bifunctional compounds of the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand that binds to the ubiquitin ligase and on the other end a moiety that binds a target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds of the present invention, consistent with the degradation/inhibition of targeted polypeptides.

Abstract: Some aspects are directed to a method of operating a circuit quantum electrodynamics system that includes a physical qubit dispersively coupled to a quantum mechanical oscillator, the method comprising measuring a parity of a first state of the quantum mechanical oscillator, subsequent to measuring the parity of the first state, measuring a parity of a second state of the quantum mechanical oscillator, the second state being different from the first state, applying a first drive waveform to the quantum mechanical oscillator, and applying a second drive waveform to the physical qubit concurrent with the application of the first drive waveform, wherein the first drive waveform and the second drive waveform are selected based at least in part on a result of comparing the measured parity of the second state to the measured parity of the first state.

Abstract: Techniques for operating a mechanical oscillator as a quantum memory are described. According to some aspects, a qubit may be coupled to a piezoelectric material such that the electric field of the qubit causes stress within the piezoelectric material. The piezoelectric material may be in contact with a crystalline substrate forming an acoustic resonator such that the qubit couples to bulk acoustic waves in the crystalline substrate via its interaction with the suitable electromagnetic pulse to the qubit may cause an exchange of energy from the qubit to the acoustic phonon system and thereby transfer quantum information from the qubit to the phonon system.

Abstract: Provided are bifunctional small molecules of Formula (I): or pharmaceutically acceptable salts thereof, wherein M represents a small organic molecule which binds, covalently or non-covalently, a kinase, such as Her3 protein kinase; L1 represents a linker; and RH represents a hydrophobic group. An example of a compound of Formula (I) is a compound of Formula (II): Also provided are pharmaceutical compositions comprising a compound of Formula (I) or (II) and methods of using such compounds for treating proliferative diseases.